Vizimpro

Vizimpro (dacomitinib) is an oral prescription medication used to treat non-small cell lung cancer. This targeted therapy helps slow disease progression in adults with specific genetic mutations. It belongs to the EGFR inhibitor class and is taken once daily. Vizimpro is available by prescription only.

Vizimpro is prescribed for adults with non-small cell lung cancer (NSCLC) that has spread to nearby tissues or other parts of the body. It is used when cancer cells have certain genetic changes, such as EGFR mutations. This medication helps control tumor growth by blocking signals that promote cancer cell division. It is typically prescribed after other treatments have been tried.

Vizimpro works by targeting specific proteins in cancer cells to slow their growth. Patients may experience side effects like diarrhea, skin rash, or dry skin as the body adjusts. These effects vary in intensity and are typically managed with supportive care. Regular monitoring helps track how the medication is working.

Vizimpro should be taken exactly as prescribed by a healthcare provider. Patients should report any severe or persistent side effects, such as breathing difficulties or severe diarrhea, immediately. It is important to attend all follow-up appointments to monitor progress. Avoid grapefruit products unless approved by a doctor.

Vizimpro may interact with other medications, including strong CYP3A4 inhibitors or inducers, which can affect its effectiveness. Patients should inform their doctor about all prescription and over-the-counter drugs they are taking. Alcohol and certain supplements may also interact, so it is best to discuss these with a healthcare provider. Always check with a doctor before starting new medications.